Company Name | Gilead Sciences Hong Kong Ltd. Taiwan Branch |
---|---|
Protocol Number | GS-TW-540-5928 |
Title of Study | A Post-Authorization Study to Evaluate Safety and Clinical Outcomes in COVID-19 Patients Treated with Veklury® (Remdesivir) in Taiwan |
Primary Objective | The primary objective of this study is to assess the overall safety profile of Veklury in COVID-19 patients, including deaths. |
Number of Sites | 5 |
Period of Study | From:2021/08/03 to:2025/Q1 |
Number of Patients | 100人 |
IRB Approval Date | National Taiwan University Hospital – 25May2021 Taoyuan General Hospital – 04Aug2021 Taichung Veterans General Hospital – 02Jun2021 Tri-Service General Hospital – 17Jun2021 Chang Gung Medication Foundation – Linkou Branch – 23Jun2021 |
Publication Plan / Date | No publication planned at this moment. |